A brief summary of the conf call:
*Future prospects: Contrast media (iodine) ( in 2 yrs), more generics due to patent expiry (like sartans).
*Drug Master file approval to happen in 6mths to 1 year for several products
*Lower profits due to increase in cost of RM’s, Shipping costs. Raw matl: solvents like tetrahydrofuran and acetonitrile, Lithium as catalyst, Coal for energy ( Steam). Still dependent on China for basic chemicals.
*Approval for Kakinada expected, Krishnapatnam after Kakinada
Overall positive about maintaining 40% OPM, capacity utilization at 85%, hopeful of further growth.
Subscribe To Our Free Newsletter |